Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. lifted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 1,085.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 107,268 shares of the company’s stock after purchasing an additional 98,223 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Twist Bioscience were worth $4,985,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock valued at $269,860,000 after buying an additional 189,791 shares during the last quarter. ARK Investment Management LLC lifted its holdings in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after acquiring an additional 237,772 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Geode Capital Management LLC raised its position in Twist Bioscience by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock valued at $63,895,000 after purchasing an additional 6,908 shares during the period. Finally, First Light Asset Management LLC acquired a new position in Twist Bioscience during the fourth quarter worth $56,984,000.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TWST. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. dropped their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Guggenheim reissued a “buy” rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. The Goldman Sachs Group reduced their price objective on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Finally, Robert W. Baird decreased their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.40.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $30.93 on Friday. The stock has a market cap of $1.85 billion, a P/E ratio of -9.15 and a beta of 2.54. The company has a fifty day simple moving average of $37.82 and a 200-day simple moving average of $43.29. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $28.46 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Equities analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 689 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the transaction, the insider now owns 110,849 shares in the company, valued at $4,173,464.85. This represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 2,402 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the transaction, the chief executive officer now directly owns 662,692 shares in the company, valued at approximately $27,110,729.72. The trade was a 0.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,991 shares of company stock worth $742,654 over the last three months. Insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.